SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is attracting significant investor attention following an oversubscribed private placement, which is fueling excitement around the potential of its lead clinical pipeline asset, FB102. While the community is actively debating the stock's massive volatility and potential for further dilution, traders are closely monitoring price action for signs of a continued short squeeze or a potential reversal.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors debate the impact of the company's recent tender progress in Kenya and its long-term strategic role in the Western rare earth supply chain. While some community members are concerned by recent price volatility and project timelines, others highlight significant institutional interest and the geopolitical demand for domestic access to heavy rare earth deposits.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma (IMMX) is experiencing significant market interest driven by anticipation of upcoming Phase 2 trial data for its NXC-201 therapy, a potential breakthrough in AL amyloidosis treatment. The community is actively discussing the company's recent leadership transition, the strategic buildup of institutional ownership, and the potential for a regulatory-led rerating as the firm moves toward pivotal trial readouts.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the subject of intense debate as investors weigh the company's aggressive capital spending on AI and robotics against short-term earnings misses and significant price volatility. The community remains deeply polarized, with active discussions focusing on whether the current dip represents a generational buying opportunity for the long-term potential of autonomous systems or a fundamental breakdown of the brand's growth narrative.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors digest a high-profile potential acquisition of AtaiBeckley to bolster its neuroscience portfolio alongside continued dominance in the obesity and diabetes markets. The community remains focused on the long-term growth potential of its GLP-1 pipeline, balancing institutional bullishness against legal and competitive pressures from peers like Novo Nordisk.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta is trending following a better-than-expected earnings report that showcased resilient travel demand and revenue growth, though the stock's focus remains on management's cautious guidance regarding rising fuel costs. The community is actively debating whether Delta's premium-focused strategy and refinery asset are enough to offset geopolitical headwinds that have impacted fuel prices and overall airline margin guidance.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors eagerly anticipate upcoming Phase 3 IZAR-1 data, with community discussion centered on the potential for a significant re-rating of the stock following this clinical milestone. Sentiment is bolstered by ongoing speculation regarding potential M&A activity within the immunology sector, driving high engagement as shareholders monitor management's guidance on the trial's readout timeline.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending due to a 69% jump in quarterly liquefaction fees, highlighting the company's ability to capitalize on elevated global energy prices amid ongoing supply disruptions in the Strait of Hormuz. Investors are actively debating the stock's potential for a significant rerating as earnings approach and the firm moves toward full commercial operations at key expansion projects.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing significant volatility as market participants weigh aggressive AI infrastructure expansion against heavy short interest and macro-level uncertainties. The community remains sharply divided, with bulls pointing to the company's multi-year contract pipeline and data center demand, while bears focus on dilution concerns and broader sector-wide valuation pressures.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is under significant market pressure as traders debate the company's valuation ahead of an imminent share lock-up expiration, leading to heavy speculation on whether recent technical launch successes can offset cooling sentiment. The community remains deeply divided, with bulls pointing to long-term infrastructure and Starlink potential while bears focus on cash burn and the risk of massive insider selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy

Rein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Down 51.4% in April

Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 236,711...

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Rein Therapeutics Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

RNTXRein Therapeutics, Inc. Common Stock

Fundamentals

Latest RNTX News